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Introduction
Over the last decades, the survival of children diagnosed with 
cancer in developed countries has increased substantially. Although 
individual prognosis varies according to type of cancer, available 
US data indicates that between 1975 and 1995 mortality from 
childhood cancer declined with almost 40%.1 The five-year survival 
rate of all combined childhood cancers is now approximately 80%. 
However, in developing countries the cure rate is much lower, due 
to multiple factors, including late diagnosis, under-diagnosis and 
advanced treatments not always being available. A lack of accurate 
epidemiological data makes the exact rate unknown. 2 HIV-related 
immunosuppression further increases the incidence of certain types 
of cancers in children, e.g. Kaposi’s sarcoma and lymphomas. HIV-
infection and its co-morbidities such as tuberculosis (TB) make it 
more difficult to treat diagnosed malignancies.3 
Adequate nutrition during cancer plays an important role in clinical 
outcome measures, such as treatment response, quality of life and 
cost of care. However, in a recent critical review of important aspects 
of nutrition in children with cancer it was found that the importance 
of nutrition in children and young adults with malignancies is still 
underestimated.4 Between 5 and 50% of children and young adults 
with cancer experience malnutrition at diagnosis, depending on the 
diagnosis and the malnutrition criteria used. This is due to tumour- 
and treatment-related factors.5 During treatment this figure can 
increase with 40 -80%.6 Children are particularly vulnerable to 
malnutrition due to increased substrate needs related to the disease, 
treatment and limited reserves. At the same time, children have 
increased energy and nutrient requirements to attain appropriate 
growth and development. 
On the other side of the coin is the growing population of childhood 
cancer survivors. Children with malignancies tolerate the acute 
side-effects of antineoplastic agents better than adults, but the 
growing child is more susceptible to long-term diseases that have 
implications for later life.1 In a recent report comparing the health 
status of 10 397 survivors of childhood cancer treated from 1970 
to 1986 with 3 034 of their siblings, 62% of the survivors had at 
least one chronic health condition, and 27% had a serious or life-
threatening condition such as stroke, heart disease or kidney failure. 
Survivors were 15 times more likely to develop a second malignancy 
than their siblings. Adverse health behaviours later in life, such as 
smoking, drinking, poor diet and lack of exercise may increase the 
risk of developing some of these complications.7
Malnutrition in childhood cancer
The Free Medical Dictionary defines malnutrition as “the condition 
that develops when the body does not get the right amount of 
the vitamins, minerals, and other nutrients it needs to maintain 
healthy tissues and organ function”.8 Other definitions focus on 
protein-energy imbalances. More recently the American Society for 
Parenteral and Enteral Nutrition (ASPEN) has accepted Soeters and 
Schols’s9 umbrella definition of malnutrition: “A subacute or chronic 
state of nutrition, in which a combination of varying degrees of 
overnutrition or undernutrition and inflammatory activity has led to a 
change in body composition and diminished function.”10
An adequate protein-energy balance is needed to sustain age-
appropriate growth and maintenance. Although there is currently no 
consensus definition for malnutrition, weight and height parameters 
are most often used as indicators for malnutrition, but these are 
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not necessarily appropriate for children with cancer. Those with 
solid abdominal masses (neuroblastoma, hepatoblastoma, Wilms 
tumour) may present with normal weights due to the mass of the 
tumour. Furthermore, undetectable nutritional depletion of one or 
more micronutrients occurs in normal-, under- and/or over-weight 
children. Current data regarding the prevalence of malnutrition in 
children with cancer is influenced by different diagnostic techniques 
used in nutrition assessment, type and stage of cancer during 
assessment, the child’s individual susceptibility toward malnutrition 
and treatment regimens as well as the non-specific definition of 
malnutrition.4 Pathophysiological mechanisms that contribute to the 
development of malignancy induced malnutrition and growth failure 
include: i) complex interactions between energy and substrate 
metabolism; ii) hormonal and inflammatory components; and 
iii) alterations in metabolic compartments resulting in increased 
mobilization and oxidation of substrates and loss of body proteins. 
The type, stage and metastatic status of the disease and treatment 
modalities are some of the main risk factors for malnutrition.4
Malnutrition in cancer patients is further aggravated by cancer 
cachexia. In contrast to simple starvation where there is a relative 
maintenance of lean body mass at the expense of body fat, cancer 
cachexia is characterized by profound and progressive loss of both 
lean body mass and body fat. Although malignancy induced cachexia 
is not yet fully understood, it seems that the body’s compensatory 
mechanisms to conserve protein during simple starvation and 
decrease energy expenditure to allow prolonged survival are either 
lost or inhibited in certain cancers.4,11,12 
Management of malnutrition in the paediatric cancer survivor
The challenge in the management of children with malignancy 
is to assess the nutritional needs of the paediatric oncology 
patient to provide the optimal nutrition intervention to prevent 
or treat malnutrition and prevent its consequences. Short-term 
consequences include muscle and fat wasting with changed body 
composition, decreased tolerance and response to chemotherapy, 
treatment delays, biochemical disturbances such as anaemia 
and hypoalbuminaemia and higher susceptibility to infections. 
Long-term consequences include growth impairment, impaired 
neurodevelopment, abnormal bone density, decreased quality of life 
and increased risk for secondary cancers.4
In summary we therefore can say that we know where we stand, 
in that:
• Many of newly diagnosed children with cancer will be mal-
nourished or become malnourished during the course of 
treatment.
• Malnutrition (over- and under-nutrition) will negatively impact on 
the course of the disease and its treatment due to changes in 
body composition.
• Malnutrition, in many cases, impacts on the long-term human 
potential and quality of life of the survivor of childhood cancer.
Nutritional assessment
“Adequate nutrition assessment is paramount for the decision 
making process of nutritional intervention”.6 The A, B, C, D of 
nutritional assessment must be followed, but obstacles will be faced 
along the way. 
Anthropometrics: Weight is not a reliable indicator in an acute care 
setting due to dehydration, over-hydration, and disease mass and is 
not an indicator of muscle loss. Arm anthropometry is recommended 
as it offers advantages over measures of height and weight and 
provides useful assessment of nutritional status, especially in 
developing countries.13 The question however remains which 
standard references to use in the childhood cancer setting.
Biochemical data: Although data of blood concentration of nutrients 
and proteins can serve as a proxy of a patient’s current nutritional 
status, they need to be interpreted with current hydration status, 
medications and drug-nutrient interactions in mind. For instance, 
serum albumin, a marker of protein status during starvation, is not 
useful during acute disease, because it is a negative phase protein 
that decreases during the acute phase response. Nevertheless, as a 
marker of inflammation and acute illness, which is usually associated 
with reduced appetite and nutrient intake, hypoalbuminemia still 
suggests a need for nutritional intervention. As such, albumin is 
often monitored together with C-reactive protein (CRP) to distinguish 
between nutritional and inflammatory causes of low albumin and as 
a means to assess recovery from, for instance, an acute infection.1,14 
As another example, lower antioxidant levels have been documented 
and are associated with increased risk of toxicity (dose reductions), 
infections, chemotherapy delays, days spent in the hospital and 
decreased quality of life.6 A lower dietary intake of antioxidants had 
similar effects.15,16 
Clinical assessment: This is particularly important in children who 
should be assessed for clinical signs and symptoms of depleted 
muscle and fat stores as well as micronutrient deficiencies.17
Diet history: Apart from the usual information gathered during a 
diet history, the Children’s Oncology Group (COG) recommends 
that the history must also include information about the use of 
supplements, herbs, or alternative therapies.17 It is estimated that 
up to 85% of the pediatric oncology population use some form of 
alternative medicine, including dietary supplements. Although some 
such supplements may be beneficial, others may interact with 
medications or cause adverse effects. Patients and their families 
may not always feel comfortable to share their use of alternative, 
often cultural medical and/or food practices. Therefore an open and 
non-judgemental approach is needed to encourage families to share 
such practices so as to allow alternative modalities that are deemed 
safe and appropriate to be integrated in the patient’s treatment. 
Well- designed research on the use of alternative dietary therapies 
in the paediatric oncology patients is however lacking and is needed 
to make sound recommendations.1 
Nutrition support for children with cancer
A relative paucity of data on best practices contributes to the 
challenges in achieving the goals of nutrition support (Table I). 
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Criteria for intervention
Currently there are no universally agreed guidelines for nutrition 
intervention in the paediatric oncology population. In an international 
survey conducted by the COG, it was found that no standardized 
nutrition protocols were being employed for nutrition intervention. 
The effect of the varied and variable nutrition practices on the quality 
of life, toxicity of cancer treatments and outcome in children with 
cancer remains largely unknown. As a result of this the COG Nutrition 
Committee developed an algorithm as a general guideline for 
nutrition intervention in an effort to establish a base for appropriate 
clinical trials about nutrition and its impact on the child with cancer.18 
Nutrient requirements
There are no specific guidelines for nutrient requirements or the 
changes that occur in the paediatric oncology population. Several 
tools are available to estimate energy and nutrient needs of the 
child with cancer, including age appropriate Dietary Reference 
Intakes (DRIs) and the World Health Organization’s (WHO) equations 
for basal metabolic rate. The difficulty in estimating nutrient 
requirements is further augmented by the wide age range of 
paediatric patients and age specific requirements, ranging from 
an infant weighing about 3 kg with minimal reserves to an obese 
adolescent weighing 100 kg.1,4,17,18 The COG recommends that 
(i) cancer treatment may increase energy needs by approximately 
20% and protein needs by as much as 50%; (ii) poor treatment 
related dietary intake may necessitate a daily multivitamin and 
mineral supplement to meet daily recommended intake; and 
(iii) fluid status should be assessed and monitored to ensure proper 
hydration.1
Enteral or parenteral nutrition support?1
When oral intake remains inadequate to support growth or nutrition 
repletion in a child with cancer, enteral nutrition (EN) should be 
considered before the initiation of parenteral nutrition (PN). EN, 
in the presence of an intact gastrointestinal tract, preserves gut 
integrity and prevents bacterial translocation, enhances immune 
response and reduces the risk of infections.13,17 Studies in paediatric 
oncology patients have demonstrated that EN is successful 
in maintaining adequate nutritional status and in reversing 
malnutrition. Unfortunately, the use of EN is inconsistent.19 Some 
of the treatment related side effects, such as mucositis discourage 
the use of EN. In addition, children may have neutropenia or 
thrombocytopenia that can increase their risk for bleeding when 
the tube is inserted; however, clinical trials have not supported 
these theoretical risks.5,20,21 There is currently no evidence-based 
guidelines about the particular composition of EN in the paediatric 
oncology population. The three-way diet–chemotherapy–cancer 
interaction needs to be explored to answer questions about key 
gene expression and genetic pathway alterations by specific 
nutrients and/or combinations of nutrients.22 Supplementation with 
glutamine is reported to relieve severe mucositis, but clear evidence 
remains in need of confirmation.23-25 Equally, there is no consistent 
of confirmed evidence regarding the use of pre- and probiotics in 
this patient population. The American Academy of Paediatrics (AAP) 
does not recommend their use in seriously or chronically ill children 
until the safety of administration has been established.26 Pre- and 
probiotics may further alter anticancer drugs’ pharmacokinetics.22 
The use of anti-oxidants is controversial as there are arguments for 
and against their inclusion in cancer treatment regimes. The findings 
of such small scale studies with many uncontrolled variables are 
inconsistent and in adequate to guide clinical practice.27
Contraindications to EN are similar to those in other diseases. If no 
EN is possible, PN is indicated without delay. A delay of three to seven 
days as suggested by some is thought to be detrimental to children 
with preadmission protein energy malnutrition (PEM) and/or history 
of poor dietary intake.1,4,17,28 When considering PN the impact of 
specific lipid formulations should be considered. Recent knowledge 
about the immunomodulating actions of ω-3 polyunsaturated fatty 
acids indicates that eicosapentanoic acid and docosahexanoic acid 
may have different effects on the function and gene expression of 
immune cells.29,30 Furthermore, parenteral nutrition–associated liver 
disease (PNLD) remains a dreaded complication of PN in children.31 
New intravenous lipid emulsions containing fish oil have been 
shown to be beneficial and safe in the management of PNLD in 
paediatrics, but their impact on cancer treatments need to be further 
explored.22,32,33 Whichever route of nutritional repletion is used, it 
needs to be borne in mind that the malnourished child with cancer 
is at risk of refeeding syndrome, should aggressive nutritional 
rehabilitation be implemented.17 
In a recent Cochrane Review to determine the effects of any form 
of PN or EN support in children and young people with cancer 
undergoing chemotherapy, the authors concluded that there is 
limited evidence from individual trials to suggest that PN is more 
effective than EN in well-nourished children and young people with 
cancer undergoing chemotherapy. The evidence for other methods 
of nutritional support remains unclear. No studies were identified 
comparing the nutritional content in the PN or EN groups of studies 34
Where do we need to go?
Analysis of childhood cancer statistics in the US has shown that the rate 
of decline in mortality from most cancers has decreased. This latter 
has been attributed to the consistent improvements in outcome from 
sequential clinical trials by optimizing delivery of standard cytotoxic 
agents and other conventional therapeutic approaches (surgery, 
radiation therapy, and hematopoietic stem-cell transplantation). With 
the advent of targeted therapeutics, which is currently in its infancy, 
further improvements can be expected.35 At the same time it has 
been acknowledged that there is paucity of nutritional investigation 
in children with cancer that needs to be addressed.18 Some of the 
areas to explore include the biological modification of disease by 
nutrients, improved tolerance of chemotherapy and amelioration of 
Table I: Goals of nutrition support in children with cancer
Sustain and promote normal growth17
Reverse malnutrition, if present17
Prevent future malnutrition17
Promote normal eating behaviours1
Improve quality of life1
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toxicity.6 Examples of nutrients being investigated are glutamine, 
ω-3 polyunsaturated fatty acids, pre- and probiotics that are 
therapeutic factors that potentially modulate gastrointestinal toxicity 
related to cancer treatments. Mechanisms underlying the action 
of these nutrients are being unravelled and will lead to the better 
understanding of their potential clinical benefit or detriment. Optimal 
strategies to translate these findings into clinical care however still 
remain to be elucidated.22 Furthermore, cancer cachexia is another 
area of ongoing research, and current treatment options for cancer 
malnutrition in adults, including drugs and anabolic agents are of 
limited use in the paediatric cancer population due to adverse effects 
in a growing and immature child and need to be further investigated.4
The identified knowledge gaps are being addressed in the developed 
world and will no doubt further improve clinical outcomes among the 
children of the developed world, in so-called High Income Countries 
(HIC). But where do we have to go in the developing world, in Middle 
(MIC) and Low Income Countries (LIC), in which 80% of the world’s 
children live, and where poverty, lack of public health infrastructure, 
high under 5-year mortality rates, and low childhood cancer cure 
rates are pervasive?36 The challenging question often asked is: “Can 
or should cancer treatment and supportive care take precedence 
over much bigger health problems facing children in LIC”? 
Last but not least: where do we need to go with survivors of 
childhood cancers?
We are in the era where survivors of childhood cancers has increased 
to up to 80% of cases due to the introduction of chemotherapy and 
improved associated treatment modalities. The increasing number 
of cancer survivors has brought to the fore the need and importance 
of identifying appropriate nutrition interventions not only to improve 
cancer outcomes but also to prevent and/or manage chronic health 
issues, improve quality of life, and decrease health care costs. This 
change in the landscape of paediatric oncology underscores the 
need for further research to support the development of evidence-
based nutrition guidelines for cancer survivors.37
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